http://www.globes.co.il/en/article-novartis-reportedly-in-talks-to-buy-gamida-cell-1000925082
Gamida-Cell's first product was jointly developed with Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA), but the US Food and Drug Administration (FDA) retroactively tightened clinical trial requirements rendering the product's development uneconomical. The company is developing what it says is an improved product in the same field. The product is undergoing clinical trials, and because of its expected improved efficacy, justifies the high development cost. Teva has no rights to this product, making the deal with Novartis possible.
http://www.globes.co.il/en/article-novartis-reportedly-in-talks-t...
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
96.0¢ |
Change
0.025(2.67%) |
Mkt cap ! $1.096B | |||
| Open | High | Low | Value | Volume |
| 95.0¢ | 96.5¢ | 94.0¢ | $1.231M | 1.291M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 94461 | 95.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 96.0¢ | 61151 | 6 |
View Market Depth
| Last trade - 16.10pm 12/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |